At Diabetotech, we have developed more than 20 independent, peer-reviewed CGM courses covering both established and emerging glucose monitoring technologies
The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to receive orforglipron or placebo
Focus on verified purity (98%), enteric coating for enhanced absorption, transparent third-party testing, and responsible sourcing
"When you think about normalizing obesity and the treatment of it, people are used to taking a pill for hypertension or for high cholesterol, so here's another way that it just normalizes it to take a pill for a condition that we know is a chronic disease," Narula said
Licensed providers offer structured telehealth care available nationwide in all 50 states.
